LENZ Therapeutics: Presbyopia Eyedrops Look Promising

LENZ Therapeutics, Inc. (NASDAQ: LENZ ) has a market cap of $825 million, with $190 million in cash. They have a PDUFA date of 8/8/2025 for their drug, aceclidine (1.75%), for the treatment of presbyopia. Presbyopia affects 128 million people in the U.S. and is aAnalyst’s Disclosure:I/we have a beneficial long position in the shares of LENZ either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (oth ...